<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611190</url>
  </required_header>
  <id_info>
    <org_study_id>In-stent Restenosis</org_study_id>
    <nct_id>NCT05611190</nct_id>
  </id_info>
  <brief_title>CT-FFR-guided Strategy for In-stent Restenosis</brief_title>
  <official_title>Coronary CT Angiography-Derived Fractional Flow Reserve-guided Optimize Treatment Strategy for In-stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yan'an Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yan'an Affiliated Hospital of Kunming Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, randomized clinical trial to compare standard practice&#xD;
      guided by usual care testing to CT-FFR-guided management in patients with in-stent&#xD;
      restenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will randomize 294 patients with in-stent restenosis to receive either CT-FFR or&#xD;
      routine clinical assessment. In all subjects, the investigators will review all diagnostic&#xD;
      test results and determine a treatment strategy. The primary end point will be 12-month Major&#xD;
      Adverse Coronary Event (MACE) rates, defined as all cause death, non-fatal myocardial&#xD;
      infarction (MI), ischemia-driven target vessel revascularization (TVR). Secondary end points&#xD;
      will include total medical costs, and quality of life (QOL), medical radiation exposure, etc.&#xD;
      We will test noninferiority of current FFR-guided strategy compared with standard care&#xD;
      strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 12, 2022</start_date>
  <completion_date type="Anticipated">December 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month MACE</measure>
    <time_frame>12 months</time_frame>
    <description>12-month Major Adverse Coronary Event (MACE) rates, defined as:&#xD;
All cause death&#xD;
Non-fatal myocardial infarction (MI)&#xD;
Ischemia-driven target vessel revascularization (TVR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>3-month, 6-month, 24-month, 36-month</time_frame>
    <description>MACE defined as:&#xD;
All cause death&#xD;
Non-fatal MI&#xD;
Clinical-driven TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Target lesion failure (TLF)</measure>
    <time_frame>3-month, 6-month, 24-month, 36-month</time_frame>
    <description>Composite of clinically driven TLR, MI or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs</measure>
    <time_frame>6-month, 12-month</time_frame>
    <description>Total costs will be calculated from the use of all cardiac-related invasive and non-invasive tests, revascularization procedures, hospital admissions and outpatient attendances due to a cardiovascular cause, and cardiac medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire</measure>
    <time_frame>6-month, 12-month</time_frame>
    <description>Quality of life (QOL), will be assessed using the EQ-5D-VAS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire</measure>
    <time_frame>6-month, 12-month</time_frame>
    <description>angina status, will be assessed using the Seattle Angina Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative radiation exposure</measure>
    <time_frame>6-month, 12-month</time_frame>
    <description>Cumulative radiation exposure within 6-month and 12-month of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants randomized to usual care will be evaluated according to institutional standard practice. The investigators will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-FFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to a CT-FFR strategy will be assigned to non-invasive CT-FFR evaluation. The investigators will review the results CT-FFR, and will recommend a further ICA test if CT-FFR≤0.8. The investigators will review the results of all available diagnostic tests, including CT-FFR and ICA, and will recommend a treatment strategy accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT-FFR</intervention_name>
    <description>CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.</description>
    <arm_group_label>CT-FFR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Participants randomized to usual care will be evaluated according to institutional standard practice.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) &gt;18 years old;&#xD;
&#xD;
          -  (2) ability to provide informed consent;&#xD;
&#xD;
          -  (3) previous PCI who underwent CCTA and have at least 1 lesion with a percent diameter&#xD;
             in-stent stenosis between 30% and 90% in a coronary artery with a ≥2.25 mm reference&#xD;
             vessel diameter by visual assessment;&#xD;
&#xD;
          -  (4) accepted further clinically indicated coronary testing, coronary arteriography, or&#xD;
             FFR, or IVUS, or PCI, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Prior coronary artery bypass surgery (CABG), heart valve surgery, cardiac&#xD;
             pacemaker, or implanted cardiac defibrillator;&#xD;
&#xD;
          -  (2) Target vascular stents were evaluated for implantation within one month;&#xD;
&#xD;
          -  (3) unstable clinical conditions including acute chest pain, cardiogenic shock,&#xD;
             congestive heart failure (NYHA grade III or IV), unstable blood pressure (systolic&#xD;
             blood pressure &lt; 90mmHg) or acute pulmonary edema;&#xD;
&#xD;
          -  (4) Acute myocardial infarction occurred within 7 days before enrollment, and left&#xD;
             ventricular ejection fraction ≤40%;&#xD;
&#xD;
          -  (5) Other severe cases are not suitable for clinical trials including complex&#xD;
             congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia,&#xD;
             tachycardia, severe asthma, severe or very severe chronic obstructive pulmonary&#xD;
             disease (COPD) and severe chronic renal damage;&#xD;
&#xD;
          -  (6) Contraindication to beta blockers, nitroglycerin, adenosine, or allergy to iodine&#xD;
             contrast agents;&#xD;
&#xD;
          -  (7) Pregnancy or pregnancy status unknown;&#xD;
&#xD;
          -  (8) Life expectancy &lt;1 years;&#xD;
&#xD;
          -  (9)Repeated enrollment;&#xD;
&#xD;
          -  (10) Any other factors that other researchers consider not suitable for inclusion or&#xD;
             completion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Xue</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yan'an Affiliated Hospital of Kunming Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Xue</last_name>
    <phone>13987199913</phone>
    <email>Xueqiang3513@126.com</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary CT Angiography-derived Fractional Flow Reserve</keyword>
  <keyword>In-stent Restenosis</keyword>
  <keyword>Major Adverse Coronary Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

